Webinar Alert! Building Robust Potency Assays with In-Cell Western Assay Protein Expression Readouts Register Today!

Bridging Preclinical and Clinical Immunogenicity Data for AAV-based Ocular Gene Therapies

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Bridging Preclinical and Clinical Immunogenicity Data for AAV-based Ocular Gene Therapies

Bridging Preclinical and Clinical Immunogenicity for Ocular AAV Therapies

CELL & GENE | RNA | BIOLOGICS

  • Translational insights for de-risking immune responses in the eye.*

Successful development of AAV-based ocular gene therapies requires a sophisticated understanding of potential immune responses within an immune-privileged environment. A proactive immunogenicity assessment strategy is fundamental for de-risking clinical programs and ensuring patient safety. This involves characterizing pre-existing and treatment-emergent immunity to both the AAV capsid and the transgene product. Franklin Biolabs provides a comprehensive bioanalytical framework to bridge preclinical immunogenicity data with clinical monitoring strategies, supporting an average 18-24 month IND timeline.

    How do you assess pre-existing neutralizing antibodies (NAbs) against novel AAV serotypes for ocular delivery?

    A: We utilize validated cell-based NAb assays tailored to the specific AAV serotype (e.g., AAV7, AAV8) and transgene. Screening human serum samples from relevant populations establishes a baseline prevalence, which informs clinical trial inclusion/exclusion criteria and helps interpret treatment-emergent NAb responses.

    What is the regulatory expectation (e.g., MHRA) for immunogenicity data in an IND package for an ocular AAV therapy?

    A: Regulators expect a multi-tiered risk assessment. This includes data on pre-existing NAbs, a validated method for detecting anti-drug antibodies (ADAs) against the capsid and transgene, and an evaluation of cell-mediated immunity. The data must be sufficient to justify the proposed clinical monitoring plan.

    How does the immune-privileged status of the eye impact preclinical immunogenicity study design?

    A: While the eye is immune-privileged, intraocular AAV administration can still lead to systemic exposure and immune activation. Study designs must account for this by including systemic sampling time points for ADA and T-cell analysis, alongside local ocular tissue analysis and Histology to assess for inflammatory infiltrates.

    Which bioanalytical assays are most predictive of clinical immunotoxicity for intraocular AAV administration?

    A: A combination of assays provides the most predictive data set. High-titer NAb responses are strongly correlated with reduced efficacy. The presence of capsid- and transgene-directed T-cell responses, measured by platforms like ELISpot, can indicate a potential for inflammatory responses that may compromise safety and long-term transgene expression.

A senior scientist with grey hair is mentoring a diverse group of younger scientists or students in a laboratory setting.

The Ocular Immunogenicity Challenge

The eye’s immune-privileged status does not grant AAV vectors immunity from host surveillance. Both innate and adaptive immune responses can be triggered by the AAV capsid or the transgene product, potentially limiting therapeutic efficacy and durability. The selection of an appropriate AAV serotype is a primary consideration, as certain novel serotypes demonstrate superior transduction of retinal structures, which may influence the nature of the host immune response (PMID: 18278824).

A comprehensive preclinical assessment must characterize the vector’s complete immunogenic profile. This requires a bioanalytical program capable of detecting humoral and cellular responses with high sensitivity. Understanding the kinetics and magnitude of these responses in relevant preclinical models is key to predicting clinical outcomes.

A Framework for Preclinical to Clinical Translation

A robust immunogenicity risk assessment integrates data from multiple bioanalytical platforms. This approach provides the Immunogenicity Intelligence for Advanced Therapies needed to inform clinical trial design.

Key components of this framework include:

  • Neutralizing Antibody (NAb) Screening: Establishing the prevalence of pre-existing NAbs in the target patient population.

  • Anti-Drug Antibody (ADA) Assessment: Developing and validating tiered assays to detect and characterize binding antibodies against both the AAV capsid and the transgene protein.

  • T-cell Response Evaluation: Using functional assays like ELISpot or intracellular cytokine staining to measure antigen-specific T-cell activation.

  • Data Integration: Correlating bioanalytical findings with non-target tissue biodistribution and Histology data to build a complete safety profile.

Long-term monitoring in preclinical studies is necessary to evaluate the durability of immune responses, a principle underscored in AAV platform development where sustained immunogenicity is a key characteristic (PMID: 33442684). This long-term data directly informs the design of the clinical monitoring plan.

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is our trusted partner in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
– Biotech Partner

Our programs have supported a 100% IND success rate for our partners since 2019. The Franklin Biolabs brand, launched in 2024, continues this legacy of scientific and regulatory excellence from our >100,000 sq ft GxP-compliant facility.

A senior scientist leads a discussion with a group of diverse junior scientists in a bright, modern laboratory setting.

A close-up shot of a scientist in a lab coat and blue gloves using a micropipette to transfer a liquid sample into a small test tube.

Commitment to Animal Welfare

All studies are conducted in our USDA-licensed facilities. We strictly adhere to the 3Rs principles (Reduction, Refinement, and Replacement) to ensure the most ethical and scientifically sound outcomes.

Integrated Bioanalytical Capabilities

We provide a suite of validated assays to support every stage of your ocular gene therapy program, from discovery through to post-market clinical monitoring.

Assay Platform Target Analyte Key Application
Cell-Based NAb Assay Neutralizing Antibodies Patient screening & eligibility, efficacy assessment
Multi-Tiered ELISA/MSD Anti-Capsid & Anti-Transgene ADAs Safety & immunotoxicity monitoring
ELISpot / ICS Antigen-Specific T-cells Cellular immunogenicity risk assessment
Luminex / MSD Cytokines & Chemokines Mechanistic insight into inflammatory responses

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities